TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05163977

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blumgart Anastomosis
Description: The anti-mesenteric border of the jejunal loop proximal to the hepatico-jejunostomy is brought against the pancreatic stump. With the pancreatic stump retracted by the stay sutures, the transected end of pancreatic duct is first identified and secured by means of a blunt tipped probe. Each trans-pancreatic, suture was performed using a single Polydioxanone (PDS) 3 -0 blunt needle. We usually take 4 sutures, 2 on each side of the duct. The process is repeated in the same manner with the remaining sutures which are tightened at the end to approximate the jejunum loop to the stump. A small stab incision is then made at the anti-mesenteric border of the jejunum and a duct to mucosa anastomosis is constructed using an interrupted 5-0 Prolene. The process is completed by placing each of the retained needles through the seromuscular layer of the anterior jejunal wall and each knot is tied over the jejunal wall which is then warped over the cut end of the stump

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cattell Warren Anastomosis
Description: It is a two layer, interrupted, end to side pancreatico-jejunostomy. First an interrupted sutures between the posterior capsule and the seromuscular layer of the jejunum was constructed using PDS 3-0 , then a duct to mucosa interrupted sutures were taken using PDS 5-0 and finally interrupted sutures between the anterior capsule and the jejunum . The main difference here is that the sutures are taken in a conventional way which is tangential to the pancreatic capsule and parenchyma
Study: NCT05889377

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket preservation
Description: Socket preservation will be done after tooth extraction. For each group we will use a bone substitute.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket preservation
Description: Socket preservation will be done after tooth extraction. For each group we will use a bone substitute.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Socket preservation
Description: Socket preservation will be done after tooth extraction. For each group we will use a bone substitute.
Study: NCT04464993

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Earn sedentary screen time through moderate-vigorous physical activity: EARN
Description: Earn sedentary screen time through moderate-vigorous physical activity: EARN Participants assigned to the EARN component will earn SST by engaging in a \>5 min continuous bout of exercise (as defined by Fitbit minutes \>4 metabolic equivalents). They will earn SST on a 3:1 ratio up until they reach their baseline level of MVPA (5 mins of exercise earns 15 mins of SST). They will receive behavioral strategies to reduce screen time within the app (e.g., self-efficacy, barriers, exercising safely) and a planning tool for scheduling MVPA.
Study: NCT04540302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Merit WRAPSODY Endovascular Stent Graft
Description: Target lesion treated with stent graft placement

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Merit WRAPSODY Endovascular Stent Graft
Description: Target lesion treated with stent graft placement

Intervention type: DEVICE
Group type: OTHER
Intervention: PTA
Description: Target lesion treated with standard percutaneous transluminal angioplasty (PTA)
Study: NCT06714903

Intervention type: OTHER
Intervention: treatment option-sintilimab plus fruquintinib
Description: sintilimab plus fruquintinib
Study: NCT05405595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG126
Description: ADG126 and Pembrolizumab (KEYTRUDA®) combination treatment both will be dosed until progressive disease (PD), intolerable toxicities, withdrawals of consent, or up to 35 cycles.
Study: NCT06714903

Intervention type: OTHER
Intervention: treatment option-fruquintinib alone
Description: fruquintinib alone
Study: NCT06719271

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Participants this group will receive gait training in robotic assisted gait training (RAGT) three times per week for eight weeks
Description: Robotic Assited Gait Training is a device used to train children with CP how to walk in effective manner by connecting their body to the harness, robotic devices that attached to the electronic treadmill

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body Weight Supported Treadmill Training
Description: Participants in this group will receive gait training on conventional treadmill three times per week for eight weeks
Study: NCT06719297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized cognitive-sensorimotor VR/MR training
Description: Thinking task integrated walking and balance training program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard walking and balance training
Study: NCT06717191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biosimilar insulin glargine
Description: Switched to once daily injection of biosimilar insulin glargine via reusable pen and three mealtime bolus insulin injections of short-acting human insulin via needle and syringe
Study: NCT06715189

Intervention type: DIAGNOSTIC_TEST
Intervention: serum Adiponectine and Resistin
Description: corrolation between serum adiponectin and Resistin levels and degree of hepatic fibrosis

Intervention type: DIAGNOSTIC_TEST
Intervention: serum Adiponectine and Resistin
Description: corrolation between serum adiponectin and Resistin levels and degree of hepatic fibrosis

Intervention type: DIAGNOSTIC_TEST
Intervention: fibroscan
Description: hepatic fibrosis detection in type 2 diabetes mellutis

Intervention type: DIAGNOSTIC_TEST
Intervention: fibroscan
Description: hepatic fibrosis detection in type 2 diabetes mellutis
Study: NCT06717737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control group： Maintaining old exercise habits
Description: The control group will maintain their original daily habits without any intervention behaviors for them

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group：Conducted a 6-month team training intervention
Description: Spanning six months, the program incorporated aerobic training, resistance training, and functional exercises essential for rescue operations. Each training session was led by certified professionals who emphasized adherence to safety protocols and provided real-time feedback.~Central to the training process was the significance of teamwork and mutual support, with sessions conducted in small groups focused on shared objectives. This framework fostered a collaborative environment that promoted peer support and motivated participants to actively engage in their fitness regimen. The group setting enabled firefighters to encourage one another and share individual progress, thereby enhancing their sense of responsibility and belonging.
Study: NCT06715085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma Rich in Growth Factors (PRGF)
Description: The PRGF application consists of three series of infiltrations in the intervertebral disc, epidural space and facets, with a frequency of two weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid solution (Celestone Cronodose suspension for injection) in saline solution.
Description: The corticosteroid solution application consists of two series of infiltrations of solution of corticosteroid (Celestone Cronodose injectable suspension \[betamethasone\]) and saline solution in the epidural space and in the facets, with a periodicity of one month between them.
Study: NCT06719115

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: UClear
Description: Take one dose twice a day for three days with or without food, starting on Day 1 (baseline visit).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take one dose twice a day for three days with or without food, starting on Day 1 (baseline visit).
Study: NCT06715826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-NOTA-T4
Description: Enrolled patients will receive 0.05-0.1mCi/kg of \[68Ga\]Ga-NOTA-T4. ImmunoPET/CT imaging will be acquired 1 hour after \[68Ga\]Ga-NOTA-T4 injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-RESCA-T4
Description: Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-T4. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]F-RESCA-T4 injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-DOTA-H2D3
Description: Enrolled patients will receive 0.05-0.1mCi/kg of \[68Ga\]Ga-DOTA-H2D3. ImmunoPET/CT imaging will be acquired 1 hour after \[68Ga\]Ga-DOTA-H2D3 injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-RESCA-RB14
Description: Enrolled patients will receive 0.05-0.1mCi/kg of \[18F\]F-RESCA-RB14. ImmunoPET/CT imaging will be acquired 1 hour after \[18F\]F-RESCA-RB14 injection.
Study: NCT06719362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3T01
Description: Subjects will be treated with M3T01 through an IV infusion over 1 hour given every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3T01
Description: Subjects will be treated with M3T01 through an IV infusion over 1 hour given every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3T01
Description: Subjects will be treated with M3T01 through an IV infusion over 1 hour given every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3T01
Description: Subjects will be treated with M3T01 through an IV infusion over 1 hour given every 3 weeks.
Study: NCT06048926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrelizumab
Description: 200 mg/time, iv, Q3W

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel injection
Description: 50mg/m2,iv, D1, 8, 15, 22, 29, once a week, a total of 5 times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel injection
Description: 50mg/m2,iv, D1, 8, 15, 22, 29, once a week, a total of 5 times
Study: NCT06719362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3T01
Description: Subjects will be treated with M3T01 through an IV infusion over 1 hour given every 3 weeks.
Study: NCT06048926

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 25mg/m2，iv， D1、8、15、22、29，once a week, a total of 5 times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2，iv， D1、8、15、22、29，once a week, a total of 5 times

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Concurrent chemoradiotherapy
Description: Radiotherapy was given simultaneously at the time of the first dose, and the total dose of radiotherapy was 50.4 Gy, which was completed in 28 divided doses of 1.8 Gy each time, 5 times a week.
Study: NCT06048926

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Description: Radiotherapy was given simultaneously at the time of the first dose, and the total dose of radiotherapy was 50.4 Gy, which was completed in 28 divided doses of 1.8 Gy each time, 5 times a week.
Study: NCT06719362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3T01
Description: Subjects will be treated with M3T01 through an IV infusion over 1 hour given every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M3T01
Description: Subjects will be treated with M3T01 through an IV infusion over 1 hour given every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be given as standard of care to Cohort DL 5+ under Part 1 of the study. Subjects will receive 200 mg IV once every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be given as standard of care to Cohort DL 5+ under Part 1 of the study. Subjects will receive 200 mg IV once every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be given as standard of care to Cohort DL 5+ under Part 1 of the study. Subjects will receive 200 mg IV once every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be given as standard of care to Cohort DL 5+ under Part 1 of the study. Subjects will receive 200 mg IV once every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be given as standard of care to Cohort DL 5+ under Part 1 of the study. Subjects will receive 200 mg IV once every 3 weeks.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: Subjects will be treated with standard of care chemoradiation therapy consisting of TMZ 75 mg/m2 daily with concurrent radiation therapy (60 Gy administered over 6 weeks). Following chemoradiation therapy, subjects will have a 4-week break from TMZ before starting standard adjuvant TMZ 150-200 mg/m2 days 1-5 of 28-day cycles for 6 cycles. Subjects will be treated with M3T01 at the RP2D through an IV infusion every 3 weeks that will begin concurrently with chemoradiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: FOLFOX will be given as standard of care on 14 day cycles. Subjects will receive oxaliplatin 85 mg/m2 IV on Day 1, leucovorin 400 mg/m2 IV on Day 1, fluorouracil 400 mg/m2 IV push on Day 1, and fluorouracil 1,200 mg/m2 IV continuous infusion on Days 1-2 every 14 days for up to 9 cycles.
Study: NCT06715969

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Release Techniques
Description: Separate techniques will be applied to the parts of the thoracolumbal fascia that surround the erector spina, quadratus lumborum, latissimus dorsi muscles and extend in that direction to patients in the MFR group. Techniques will continue for 180 seconds, tissue shift will be carried further as relaxation is achieved. Applications Total 8 sessions will be applied twice a week by an experienced physiotherapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myofascial Induction Techniques
Description: MIT will be applied to the lumbal region by a physiotherapist trained and experienced in fascial treatments to patients in the MIT group. Applications 2 sessions per week, a total of 8 sessions will be applied, with an average of 20-25 minutes. The application principles of this technique will be as follows.~* Induction of the lumbal interfacial triangle region (stroke application) (3 min)~* Induction of the lumbal interfacial triangle region (deep induction application) (3 min)~* Cross-hands myofascial induction (3 min)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: classıcal phsyotherapy
Description: 15 sessions of mictowave diathermy (MDD), Vacuum Interference, Infraruj and Classic waist exercise program will be applied to patients in this group.
Study: NCT06719518

Intervention type: DEVICE
Intervention: ViTrack device
Description: In the operating room the ViTrack™ device will be applied the wrist. Monitoring will start in the operating room and will continue throughout the surgery. The device can be worn on either wrist. It will be connected to a power unit that will capture blood pressure data and stream the data to a secure laptop
Study: NCT06717815

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG11406
Description: Investigational Medical Products:~IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 10 mg and 40 mg Storage：15 \~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 tablets are orally administered twice a Day with an interval of 12±1 hours. Tablets should not be chewed or crushed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG11406
Description: Investigational Medical Products:~IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 10 mg and 40 mg Storage：15 \~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 tablets are orally administered twice a Day with an interval of 12±1 hours. Tablets should not be chewed or crushed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG11406
Description: Investigational Medical Products:~IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 10 mg and 40 mg Storage：15 \~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 tablets are orally administered twice a Day with an interval of 12±1 hours. Tablets should not be chewed or crushed.
Study: NCT06716203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: 5 mg BGM0504 Administered SC
Description: Drug: BGM0504 Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: : 10 mg BGM0504 Administered SC
Description: Drug: BGM0504 Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Drug: Placebo Administered SC
Description: Drug: Placebo Administered SC
Study: NCT06716138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANS03
Description: ANS03 is a rationally next generation TKI targeting both ROS1 and NTRK developed by Shenzhen Avistone Biotechnology (the sponsor).
Study: NCT06716450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiplo TP/HIV Antibody Test
Description: The Multiplo TP/HIV Antibody Test (MedMira Laboratories Inc., Halifax, NS), \[Multiplo TP/HIV Test\] is a single use, rapid, vertical-flow in vitro qualitative immunoassay for the detection of antibodies to Human Immunodeficiency Virus (HIV) Type 1/Type 2 and Treponema pallidum (Syphilis) in human fingerstick blood. The Multiplo® TP/HIV Test is intended as an aid in the diagnosis of HIV1/2 and Syphilis infections in patients with signs and symptoms of HIV and syphilis. The test is intended for use by trained personnel in medical facilities, clinical laboratories, emergency care situations, and physicians' offices as an in vitro diagnostic device capable of providing results in less than five minutes. The Multiplo TP/HIV Test has not yet sought approval for self-testing. All required pre and post-test counselling guidelines must be followed in each setting in which the Multiplo TP/HIV Test is used. Results are read visually.
Study: NCT06717009

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Preoperative three-dimensional reconstruction
Description: On the basis of conventional CT/MRI, the patient will undergo 3D reconstruction within 48 hours before surgery. The surgeon/researcher will conduct surgical planning according to the results of the 3D reconstruction and perform robot-assisted laparoscopic nephron sparing surgery.
Study: NCT06095960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth MOM
Description: Patients will receive enhanced standard of care plus remote blood pressure monitoring, remote thermometer, and a 10- to 14-day post-partum telehealth visit.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care
Description: Patients will receive enhanced standard of care which includes: education on symptoms and when to call their healthcare provider, comprehensive 6-week post-partum visit, and any healthcare deemed necessary by providers.
Study: NCT06113770

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preparation of the tooth to receive ready made zirconia crown
Description: Occlusal reduction 1 to 2 mm using flame bur . Open the interproximal contacts. The tooth should be reduced circumferentially by approximately 0.5-1.5mm . The preparation margin should be carefully extended and refined to a feather-edge approximately 1-2mm subgingivally .~Crown size will be determined using try in kit .
Study: NCT06441461

Intervention type: OTHER
Intervention: Primary informal caregiver at work.
Description: Employees becoming a primary informal caregiver for a child or an adolescent with mental health problems in the period from 2000 to 2018.
Study: NCT05861635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin combined with Tislelizumab
Description: Subjects who meet the requirements of the protocol will receive neoadjuvant treatment, and the specific administration arrangement is as follows:~Disitamab Vedotin, 2 mg/Kg, q2W, 8cycle Tislelizumab, 200mg, iv, q3W, 6cycle
Study: NCT05121025

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of gut microbiome and immune signatures
Description: The investigators will analyse the microbiome composition (16S rDNA-sequencing and metagenomics), microbiome activity (RNA-sequencing of stool bacteria and metabolite sampling) and immune cell activity (leukocyte RNA-sequencing) of all study groups.

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of gut microbiome and immune signatures
Description: The investigators will analyse the microbiome composition (16S rDNA-sequencing and metagenomics), microbiome activity (RNA-sequencing of stool bacteria and metabolite sampling) and immune cell activity (leukocyte RNA-sequencing) of all study groups.

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of gut microbiome and immune signatures
Description: The investigators will analyse the microbiome composition (16S rDNA-sequencing and metagenomics), microbiome activity (RNA-sequencing of stool bacteria and metabolite sampling) and immune cell activity (leukocyte RNA-sequencing) of all study groups.
Study: NCT05178784

Intervention type: DEVICE
Intervention: External Combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS) stimulation
Description: Relivion®DP is a device by Neurolief that delivers external, combined Occipital and Trigeminal Nerve Stimulation (eCOT-NS), which is proposed as a novel treatment approach for MDD. The Relivion®DP device is designed for at-home self-administration by patients; it is comprised of a headset that holds electrodes, and it is worn externally on a person's head. When activated, the device delivers mild electrical stimulation pulses which can be managed by the user. The stimulation is intended to reduce MDD symptoms.
Study: NCT05155033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV over approximately 30 minutes on Day 1 of cycles 1 and 2 during Courses 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin (IL-2) administration \[600,000 IU/kg IV bolus every 8 hours continuing for up to 4 days (maximum 10 doses)\] starting on Day 1 of cycles 1 and 2 during Course 1.
Study: NCT06114719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silymarin
Description: Subjects of the experimental group will receive silymarin (capsules containing 100 mg silymarin, expressed as silibinin) three days preoperatively. The dose they receive will be the recommended dose for the registered indications (400 mg daily, orally, divided into two doses).
Study: NCT05639881

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhancing Your Immune Health
Description: In addition to routine mental health care, subjects receive an intervention to improve their immune health literacy and self-management behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhancing Your Immune Health
Description: In addition to routine mental health care, subjects receive an intervention to improve their immune health literacy and self-management behaviors.